RYAH Group Inc. is a leading digital health care analytics and technology company with a mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments. Through the company’s IoT dose-measuring devices and AI analytics, RYAH is reshaping understanding of the value of devices combined with data, to positively impact the future treatment of patients for various medical conditions.
The company is a leading developer of dose-measuring IoT devices connected with its turn-key platform designed to aggregate and correlate HIPPA-compliant data, suitable to all participants in the patient treatment cycle. The company also specializes in customized, fully integrated, mobile applications and APIs, specifically designed to meet the needs of clinics, clinical trials, government and university research centers, for experimentation and treatment validation – significantly reducing variations in patient-related trials. RYAH unlocks data in the complete therapeutic plant lifecycle – from seed to consumption.
Since it began developing and commercializing its smart inhaler solution in 2018, the company has evolved a complete IoT device and data analytics platform that includes multiple delivery mechanisms, designed to capture anonymous patient dosing and feedback, combined with detailed strain analytics, enabling customized dosing regiments. The company has secured numerous partnerships across the globe, including establishing a footprint in the UK, USA, Australia and Canada, and it has closed several deals in the European Union, as well. The company’s Smart-Inhaler has been selected as the dose-measurement, dose-control and data analytics platform for a UK pain management study and one of the world’s most ambitious and largest clinical trials ever to be conducted in cannabis.
The company’s current portfolio incorporates an ecosystem of IoT products, each consisting of three elements: the device, the medicine-carrying component and the mobile application. The product line currently includes a Smart Dry-Herb Dose-Measuring Inhaler in the commercial stage, a Smart Transdermal Patch in the production stage and a Smart Liquid Dispensing Pen in the prototype stage.
The RYAH Inhaler is the first dry-herb inhaler that allows users to track and control how much is inhaled, providing consistent and predictable results. This inhaler connects with the RYAH Health App, which features stat-tracking and presets for temperatures and dosages, all of which can be customized to individual needs and doctor recommendations, as well as a post-session review mechanism that allows the collection of session data and feedback for further efficacy analysis for customized dosing capabilities.
RYAH’s proprietary stainless-steel cartridges for the inhaler use QR technology that contains lab testing and grower information pertaining to the specific strain, thereby mitigating elicit product use and enabling completely transparent remote medicinal analytics, from seed to consumption.
In addition, the RYAH Cartridges provide a unique closed-loop recurring revenue opportunity for the company, as the RYAH Inhaler only works with this type of proprietary cartridges that licensed partners fill with medicine. The partners benefit from all the back-end data, providing them access to consumption habits, statistics and other data on patient preferences.
The RYAH Smart Transdermal Patch is a lightweight, reusable, mobile-controlled patch used for site-specific therapies. The Patch is an Electronic Topical Delivery Patch system intended for recommendation and administration by pain relief professionals and physical and occupational therapists. The patch data and the heating element is completely IoT and controlled by RYAH’s proprietary smartphone applications, which allows scheduling and ‘boosting’ medicine release, on-demand.
The RYAH Pen is an app-controlled liquid dispenser designed to provide a precise mix of up to three medicine components to create an ‘entourage effect’, enabling customized, wide-spectrum recommendation opportunities by licensed clinicians. The Smart-Pen will feature cartridges that contain CBD, THC and other isolates such as flavonoids or vitamins, or other solutions. There is a built-in mechanism designed to control usage based on recommended dosing schedules.
RYAH MD serves as a remote and interactive patient-doctor collaboration and dosing administration platform. Doctors can remotely set dosage amounts for their patients, creating digital prescriptions for the RYAH IoT devices and tracking patient usage in real-time. RYAH MD offers features that include real-time monitoring, appointment booking, doctor-patient video calls and science-based strain recommendations, as well as promoting a better understanding of the effects and benefits of those recommendations among patients. Information is gathered from all of the RYAH devices.
The PotBot App is a medical cannabis education mobile application that leverages patented AI technology to capture structured and unstructured data to assist patients in learning about various treatments in plant-medicine based on their efficacy goals. The PotBot App is currently one of the top-rated medical cannabis educational mobile applications on the Apple App Store in the United States, with over 300,000 downloads.
Through the combination of peer-reviewed and empirical data, the PotBot App provides detailed information on the targeted and tested cannabinoid levels and associated strains from cannabis patients. The result is personalized and driven by data to inform patients of potential product matches associated with similar ailments and efficacy goals.
RYAH holds a unique position in the $100.3 billion medical plant market, with the potential to capture and capitalize on growth opportunities made available by both the IoT and Data Intelligence sectors.
In 2018, the global IoT market was valued at $212.1 billion, and it is expected to grow exponentially to $1.3 trillion by 2026, registering a CAGR of 25.68%, according to Verified Market Research (https://ibn.fm/XtkPZ).
Dr. Boris Goldstein, Ph.D., is the founder and Chairman of RYAH Group. He is a seasoned entrepreneur, investment banker and venture capitalist. He started his career as the founder of Software House HT, which grew into a worldwide corporation with over 40 offices in 17 countries. Since then, Goldstein has founded and served on the boards of directors and advisory boards for numerous companies in Silicon Valley and Silicon Alley. Goldstein brings experience in fundamental research, investment and technology, authoring multiple patents and books.
Gregory Wagner, MBA, is Chief Executive Officer and Director of RYAH Group. He has over 20 years of experience in global financial markets and entrepreneurship. Wagner has held executive roles in the United States and London. He has co-founded and built several startups from the ground up. His current licensures and degrees include FINRA Series 7, 63, 24 and 55, as well as an MBA from Fordham University. Wagner received a Certification in Innovation and Strategy from Harvard University.
- RYAH Group is a technological leader in the plant-based treatment market with its unique combination of proprietary IoT devices and data analytics, supported by patented AI technology.
- The company’s products pair a growing ecosystem of therapeutic plants with top-rated apps, devices and services.
- RYAH offers a complete remote dosage delivery and dose-monitoring platform based on data-driven analytics supported by prescribing doctors and their patients.
- The company is finalizing its anticipated listing on the Canadian Securities Exchange.
- RYAH holds a unique position on the $100.3 billion medical plant market, with the potential to capture footholds in both the IoT and Data Intelligence industries.